Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Carrie Manwaring, BS
CONTACT
Lead
University of Texas Southwestern Medical Center
With
This Phase I/II investigator-sponsored trial will evaluate the combination of zanzalintinib (XL092) and tegavivint in participants with advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations (CTNNB1, AXIN1, CREBBP, APC) who have progressed after at least one prior line of systemic therapy and are VEGFR-TKI naïve. The study employs a two-part design beginning with a Phase I dose escalation using a Bayesian Optimal Interval (BOIN) design with cohorts of 3-6 participants per dose level to determine the safety and tolerability of the combination. The dose escalation will evaluate tegavivint in combination with fixed-dose zanzalintinib. A maximum of 12 evaluable participants will be enrolled in the dose escalation phase to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tegavivint when combined with zanzalintinib.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
